A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Bicalutamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 08 Apr 2019 Planned End Date changed from 1 Oct 2024 to 1 Apr 2025.
- 08 Apr 2019 Planned primary completion date changed from 1 Oct 2023 to 1 Apr 2024.